Ad is loading...
MBOT
Price
$0.98
Change
+$0.05 (+5.38%)
Updated
Nov 22 closing price
95 days until earnings call
NVCR
Price
$17.73
Change
+$0.64 (+3.74%)
Updated
Nov 22 closing price
89 days until earnings call
Ad is loading...

MBOT vs NVCR

Header iconMBOT vs NVCR Comparison
Open Charts MBOT vs NVCRBanner chart's image
Microbot Medical
Price$0.98
Change+$0.05 (+5.38%)
Volume$128.17K
CapitalizationN/A
NovoCure
Price$17.73
Change+$0.64 (+3.74%)
Volume$657.82K
CapitalizationN/A
MBOT vs NVCR Comparison Chart
Loading...
MBOT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NVCR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MBOT vs. NVCR commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBOT is a Hold and NVCR is a StrongBuy.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (MBOT: $0.98 vs. NVCR: $17.73)
Brand notoriety: MBOT and NVCR are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MBOT: 73% vs. NVCR: 65%
Market capitalization -- MBOT: $18.57M vs. NVCR: $1.66B
MBOT [@Medical Specialties] is valued at $18.57M. NVCR’s [@Medical Specialties] market capitalization is $1.66B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBOT’s FA Score shows that 0 FA rating(s) are green whileNVCR’s FA Score has 1 green FA rating(s).

  • MBOT’s FA Score: 0 green, 5 red.
  • NVCR’s FA Score: 1 green, 4 red.
According to our system of comparison, NVCR is a better buy in the long-term than MBOT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBOT’s TA Score shows that 4 TA indicator(s) are bullish while NVCR’s TA Score has 6 bullish TA indicator(s).

  • MBOT’s TA Score: 4 bullish, 4 bearish.
  • NVCR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NVCR is a better buy in the short-term than MBOT.

Price Growth

MBOT (@Medical Specialties) experienced а +5.73% price change this week, while NVCR (@Medical Specialties) price change was +10.06% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.02%. For the same industry, the average monthly price growth was +0.79%, and the average quarterly price growth was -2.06%.

Reported Earning Dates

MBOT is expected to report earnings on Feb 26, 2025.

NVCR is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Medical Specialties (+3.02% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVCR($1.66B) has a higher market cap than MBOT($18.6M). NVCR YTD gains are higher at: 18.754 vs. MBOT (-40.244). MBOT has higher annual earnings (EBITDA): -10.75M vs. NVCR (-177.45M). NVCR has more cash in the bank: 911M vs. MBOT (8.15M). MBOT has less debt than NVCR: MBOT (245K) vs NVCR (596M). NVCR has higher revenues than MBOT: NVCR (509M) vs MBOT (0).
MBOTNVCRMBOT / NVCR
Capitalization18.6M1.66B1%
EBITDA-10.75M-177.45M6%
Gain YTD-40.24418.754-215%
P/E RatioN/AN/A-
Revenue0509M-
Total Cash8.15M911M1%
Total Debt245K596M0%
FUNDAMENTALS RATINGS
MBOT vs NVCR: Fundamental Ratings
MBOT
NVCR
OUTLOOK RATING
1..100
6179
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
7653
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MBOT's Valuation (49) in the Biotechnology industry is somewhat better than the same rating for NVCR (100) in the Medical Specialties industry. This means that MBOT’s stock grew somewhat faster than NVCR’s over the last 12 months.

MBOT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVCR (100) in the Medical Specialties industry. This means that MBOT’s stock grew similarly to NVCR’s over the last 12 months.

NVCR's SMR Rating (97) in the Medical Specialties industry is in the same range as MBOT (99) in the Biotechnology industry. This means that NVCR’s stock grew similarly to MBOT’s over the last 12 months.

NVCR's Price Growth Rating (53) in the Medical Specialties industry is in the same range as MBOT (76) in the Biotechnology industry. This means that NVCR’s stock grew similarly to MBOT’s over the last 12 months.

NVCR's P/E Growth Rating (12) in the Medical Specialties industry is significantly better than the same rating for MBOT (100) in the Biotechnology industry. This means that NVCR’s stock grew significantly faster than MBOT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBOTNVCR
RSI
ODDS (%)
N/A
Bearish Trend 6 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
N/A
View a ticker or compare two or three
Ad is loading...
MBOT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NVCR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WKEY2.090.15
+7.73%
WISeKey International Holding Ltd
PGNY15.440.47
+3.14%
Progyny
BFS40.220.44
+1.11%
Saul Centers
STRO2.51-0.02
-0.79%
Sutro Biopharma
CCJ60.11-0.82
-1.35%
Cameco Corp

MBOT and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with CORBF. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then CORBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
+5.41%
CORBF - MBOT
33%
Loosely correlated
N/A
MASS - MBOT
33%
Poorly correlated
-6.57%
OTCFF - MBOT
32%
Poorly correlated
N/A
NVCR - MBOT
31%
Poorly correlated
+3.74%
TTOO - MBOT
29%
Poorly correlated
+19.77%
More

NVCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with KIDS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then KIDS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCR
1D Price
Change %
NVCR100%
+3.74%
KIDS - NVCR
43%
Loosely correlated
-0.49%
GH - NVCR
43%
Loosely correlated
+5.39%
VCYT - NVCR
43%
Loosely correlated
+1.67%
TWST - NVCR
43%
Loosely correlated
+1.37%
MASS - NVCR
41%
Loosely correlated
-6.57%
More